Stay updated on Pembrolizumab Combo in Stage III NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T19:44:16.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has been updated to include new drug information and identifiers related to a clinical trial for non-small cell lung cancer, while significant details about the trial's design and inclusion/exclusion criteria have been removed.
    Difference
    22%
    Check dated 2025-04-16T13:26:23.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T06:54:38.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect the latest version as v2.14.3, replacing the previous version v2.14.2. The estimated last update posted has been removed.
    Difference
    0.1%
    Check dated 2025-04-01T22:50:24.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The trial details have been updated, including the estimated duration of the study and the protocol number, which has changed from Merck to MSD. Additionally, the last update posted date has been revised to reflect a more recent timeline.
    Difference
    1%
    Check dated 2025-03-25T13:38:17.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T20:21:03.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Stage III NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.